Drug Loaded Glyconanoparticle Formulation Service
Glyconanoparticles combine the biorecognition properties of sugar molecules with the physicochemical properties of nanoparticles, providing flexible applications in the delivery of anticancer drugs, neurological disorders, and more. CD BioGlyco provides a cutting-edge drug-loaded glyconanoparticle formulation service including glyconanoparticle design, preparation, characterization, preclinical studies, and application optimization. We continue to explore and innovate to provide reliable assistance in every aspect of biopharmaceutical research.
Glyconanoparticle Development
Glyconanoparticle Design
The structure and functionality of glyconanoparticles are designed according to the nature and type of different drugs and specific application requirements, including the selection of appropriate nanoparticle core materials and glycan molecule types. Based on our cutting-edge GlycoNano™ Platform, glyconanoparticles are developed including Carbohydrate-based Nanoparticle, Gold Glyconanoparticle, Silver Glyconanoparticle, Magnetic Glyconanoparticle, Quantum Dot (QD) Glyconanoparticle, and so on. We precisely control the distribution and density of sugar molecules on the surface of the nanoparticles and optimize them to improve the stability and biocompatibility of the glyconanoparticles, among others.
Glyconanoparticle Characterization
After preparation, we perform characterization analysis of glyconanoparticles, including Physicochemical Properties and Interaction analysis to ensure that they meet the design requirements.
- Various characterization techniques (e.g., scanning electron microscopy, transmission electron microscopy, X-ray diffraction, etc.) are used to evaluate the morphology observation, particle size distribution determination, and surface properties of glyconanoparticles. This step facilitates the optimization and improvement of the glyconanoparticle.
- The binding affinity and interactions with specific molecules of the glyconanoparticle are tested to ensure that it meets the needs of the application.
Glyconanoparticle Preclinical Studies
This process involves detailed studies and evaluation of stability, safety pharmacology, bioactivity, pharmacology, and pharmacodynamics of glyconanoparticles.
| Topic | Study |
|---|---|
| Stability Study | |
| Biological Characterization | |
| Pharmacodynamic Study |
|
| Pharmacokinetic Study |
|
| Safety Pharmacology |
|
Drug Loaded Glyconanoparticle Formulation
We use appropriate loading methods to load the drug onto the sugar nanoparticles to ensure that the loading amount and stability of the drug meet the needs. At the same time, we optimize the release mechanism of the drug, such as adjusting the release rate, controlling the release time, etc., to meet the specific therapeutic needs. The available drug-loaded glyconanoparticle formulation service includes the following:
Neurological Drug Loaded Glyconanoparticle Formulation Service

We specialize in providing high-quality glyconanoparticle formulation services for various neurological drugs. We use glyconanoparticle as a carrier to load neurological drugs efficiently and accurately, so as to optimize the delivery efficiency and therapeutic effect of the drugs, and to provide new ideas and methods for neurological disease therapeutic research.
Anticarcinogen Loaded Glyconanoparticle Formulation Service

Anticarcinogen-loaded glyconanoparticle formulation is an innovative solution for cancer treatment. Using glyconanoparticle as a carrier for anticancer drugs, it is precisely designed and optimized to deliver anticancer drugs to specific sites. We aim to improve the bioavailability, targeting, and stability of the drug, thus inhibiting the growth and spread of cancer cells more effectively, reducing the damage to normal cells, and providing a safer and more effective cancer treatment solution.
Cardiovascular Disease Drug Loaded Glyconanoparticle Formulation Service

We provide a one-stop cardiovascular disease drug-loaded glyconanoparticle formulation service. We utilize advanced nanotechnology and biotechnology for cardiovascular disease loading to treat cardiovascular disease more effectively by improving drug targeting, bioavailability, and stability.
Skin Disease Drug Loaded Glyconanoparticle Formulation Service

Based on our rich research experience in glyconanoparticle, we use it as a drug carrier to efficiently and precisely load skin disease drugs onto it, which enhances the transdermal absorption and targeting of the drugs, improves the efficacy of the drugs, and reduces the adverse effects at the same time.
Bone Disease Drug Loaded Glyconanoparticle Formulation Service

At CD BioGlyco, we provide a customized bone disease drug-loaded glyconanoparticle formulation service. We accurately design the structure and surface properties of glyconanoparticles and effectively load them with bone disease drug molecules for the treatment of osteoporosis, arthritis, and other bone diseases.
Eye Disease Drug Loaded Glyconanoparticle Formulation Service

We utilize the superior biocompatibility and modulated release properties of glyconanoparticles to encapsulate a wide range of drugs for the treatment of eye diseases such as glaucoma. Glyconanoparticle formulation significantly enhances the therapeutic efficacy of the eye disease drug while reducing side effects.
Antiviral Drug Loaded Glyconanoparticle Formulation Service

At CD BioGlyco, we use carefully designed glyconanoparticles as carriers for efficient loading and targeted delivery of antiviral drugs to specific sites for the effective treatment of viral diseases such as influenza.
Antifungal Drug Loaded Glyconanoparticle Formulation Service

Our researchers specialize in the development of glyconanoparticle formulations for various antifungal drugs to improve the solubility and stability of the drug and to enhance the efficiency of antifungal therapy.
Anti-inflammatory Drug Loaded Glyconanoparticle Formulation Service

We develop anti-inflammatory drug-loaded glyconanoparticle formulations for the treatment of various inflammatory diseases. By precisely controlling the release rate of the drug, the concentration of the drug is increased at the site of inflammation, the systemic side effects are reduced, and the anti-inflammatory effect is enhanced.
Painkiller Loaded Glyconanoparticle Formulation Service

This service is dedicated to the development of painkiller-loaded glyconanoparticle formulations for the relief of pain from various causes. The encapsulation of glyconanoparticles effectively improves the bioavailability and stability of painkillers and prolongs the duration of action of the drug.
Workflow
During the drug-loaded glyconanoparticle formulation service, we complete each experimental process according to strict quality standards and ensure the quality and performance of the final product. First, we have an in-depth communication with you to define the specific application requirements of the glyconanoparticle, including the type of disease, the type of drug, the mode of delivery, etc. After that, we precisely design the shape, size, and surface properties of the glyconanoparticle. Finally, through preclinical studies, we evaluate its drug loading capacity, release mechanism, stability, etc., to provide reliable support for various disease therapy studies.

Applications
- Glyconanoparticle formulation plays an important role in the development of efficient targeted therapeutic strategies for neurological diseases.
- Glyconanoparticle formulation plays an important role in the development of highly effective targeted therapeutic strategies for cancer.
- Glyconanoparticles can be loaded with multiple drugs or therapeutic agents to facilitate combination therapies and improve treatment outcomes.
Advantages
- Glyconanoparticle formulation service is customized to ensure maximum client satisfaction.
- With our extensive experience in glyconanoparticle development, we carefully design the structure and surface properties of glyconanoparticles to provide higher affinity for specific cells or tissues, enabling precisely targeted drug delivery.
- We develop appropriate glyconanoparticles for different types of drugs, which significantly improve the solubility and stability of the drug, and enhance the absorption and utilization of the drug in the body.
Publication Data
Journal: Pharmaceutics
IF: 4.9
Published: 2023
Results: This paper describes the application and biopharmaceutical implications of polymer nanoparticles in the treatment of various dermatologic conditions. Drugs are encapsulated in the inner core of polymer nanoparticles or adsorbed onto the outer shell, where their physicochemical properties are significantly improved, the degradation rate is retarded, and the release kinetics are controlled to promote retention in the skin layer. Also functionalization techniques such as polyethylene glycolization have greatly improved the therapeutic efficacy of drug-encapsulated polymer nanoparticles for promising applications.
Frequently Asked Questions
- What types of drugs glyconanoparticle be loaded with?
Glyconanoparticles are used to formulate a wide variety of drugs, including small molecules, peptides, proteins, and nucleotides. Specific glyconanoparticle formulations are developed based on the characteristics of the drug. - What services are offered in drug-loaded glyconanoparticle formulation?
- Glyconanoparticle development: Customized glyconanoparticle formulation for specific drugs.
- Characterization: Analysis of glyconanoparticle particle size, surface charge, morphology, drug encapsulation efficiency, and release profiles.
- Preclinical studies: In vitro and in vivo preclinical studies of glyconanoparticles.
CD BioGlyco provides a one-stop service for drug-loaded glyconanoparticle formulation and reliable support for all research in the biopharmaceutical field. Please feel free to contact us for more detailed information if you have a need for glyconanoparticle.
Reference
- Xie, X.; et al. Global profiling of N-glycoproteins and N-glycans in the diatom Phaeodactylum tricornutum. Frontiers in Plant Science. 2021, 12: 779307.
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





